Search

Your search keyword '"Verhamme, P."' showing total 70 results

Search Constraints

Start Over You searched for: Author "Verhamme, P." Remove constraint Author: "Verhamme, P." Publisher elsevier bv Remove constraint Publisher: elsevier bv
70 results on '"Verhamme, P."'

Search Results

1. Age-Related Differences in the Presentation, Management, and Clinical Outcomes of 100,000 Patients With Venous Thromboembolism in the RIETE Registry

2. A prognostic score to identify women at increased risk for abnormal uterine bleeding during anticoagulation for venous thromboembolism

7. Venous thromboembolism characteristics, treatment and outcomes in young adults: findings from the Registro Informatizado de Enfermedad TromboEmbólica registry

8. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

9. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

10. Timing and characteristics of venous thromboembolism after noncancer surgery

11. OC-14 Risk factors for recurrence in patients with cancer-associated venous thromboembolism: results from the Hokusai-VTE cancer study

12. Comparative clinical prognosis of massive and non‐massive pulmonary embolism: A registry‐based cohort study

13. Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation

14. Corrigendum to “Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study” [Thromb. Res. vol. 185, January 2020, pages 13–19]

15. Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry

16. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study

17. 023 Risk Stratification Using CHA2DS2-VASc and CHADS2 Scores in Patients With Chronic Atherosclerotic Cardiovascular Disease Receiving Aspirin With or Without Rivaroxaban: An Analysis of the COMPASS Trial

19. Frequency and prognostic impact of acute kidney injury in patients with acute pulmonary embolism. Data from the RIETE registry

20. Venous thromboembolism in young adults: Findings from the RIETE registry

21. Statin and all-cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE registry

22. Mortality after pulmonary embolism in patients with diabetes. Findings from the RIETE registry

23. Clinical outcome in patients with venous thromboembolism receiving concomitant anticoagulant and antiplatelet therapy

27. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial

28. Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial

29. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism

33. Age‐adjusted D‐dimer to rule out deep vein thrombosis: findings from the PALLADIO algorithm

34. Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism

35. Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism

36. Clumping factor A, von Willebrand factor‐binding protein and von Willebrand factor anchor Staphylococcus aureus to the vessel wall

37. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation

38. The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site

39. Development of a Risk Prediction Score for Occult Cancer in Patients With VTE

41. Analysis of noncatheter-associated upper extremity deep venous thrombosis from the RIETE registry

46. DVT Management and Outcome Trends, 2001 to 2014

47. Current management strategies and long‐term clinical outcomes of upper extremity venous thrombosis

49. The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders

50. The Effect of Anastomosis Time on Outcome in Recipients of Kidneys Donated After Brain Death: A Cohort Study

Catalog

Books, media, physical & digital resources